PubMed Health⌕ Search

Biomedical subjects

M Obad

Publications and source records attributed to M Obad.

9 recordsLinked to original sources
PubMed1990

[Comparison of the antihypertensive effects of bopindolol and metoprolol in the treatment of arterial hypertension].

A randomized, double blind clinical trial included 40 hypertension patients of both sexes, aged 18-70 years, with diastolic blood pressure persistently above 100 (13.33 kPa) and below 120 mm Hg (15.99 kPa). After a run-in period on placebo, one half of them was treated with bopindolol (single daily dose 1-3 mg), and the other half with metoprolol (100-300 mg daily in two divided doses). After 4 weeks of formal trial both beta blockaders had significantly decreased the elevated arterial pressure, e.g. the mean arterial pressure in the bopindolol group dropped from an average of 129.1 +/- 6.9 (17.20 +/- 0.92) to 111.6 +/- 6.1 mm Hg (14.87 +/- 0.81 kPa) or by 13.6% and in the metoprolol group from 129.8 +/- 7.1 (17.30 +/- 0.94 kPa) to 114.5 +/- 6.4 mm Hg (15.26 +/- 0.85 kPa) or by 11.8% (p less than 0.02). After 12 weeks the mean pressure was ulteriorly lowered to some 104.3 mm Hg (13.90 kPa) on bopindolol and to some 106.0 mm Hg (14.12 kPa) on metoprolol. The heart rate was expectedly slowed down, from an average of 95 to 69 b.p.m. with bopindolol (27.4% decrease, p less than 0.001) and from 99 to 67 b.p.m. with metoprolol (32.3% decrease, p less than 0.001). The other parameters, including the laboratory results did not change appreciably during this study. Clinically relevant side-effects were not registered, and the observed between-group differences did not reach the level of statistical significance. It is concluded that bopindolol and metoprolol are beta-adrenergic blockaders of comparable antihypertensive efficacy.

Adolescent↗
PubMedDate not supplied

[Controlled comparison of nicardipine and propranolol in the treatment of arterial hypertension].

A randomized collective comparative study between nicardipine (N) and propranolol (P) was conducted over a period of 7 weeks in thirty hypertensive patients of both sexes, aged from 20 to 65 years, with the diastolic pressure over 100, but below 120 mmHg. Thirteen examinees were given N (60-120 mg daily) and seventeen P (120-240 mg daily); the groups were comparable according to a series of relevant parameters. In the placebo-period the mean arterial pressure (MAP) was slightly lowered, by 4.4% (p greater than 0.20). MAP was, however, considerably lowered already at the end of the second week of active treatment both in the N group (from 135.1 +/- 7.4 to 116 +/- 10.8 mmHg, or by 19.1%; P less than 0.01), as well as in the P group (from 131.6 +/- 8.1 to 117 +/- 9.1 mmHg, by an average of 11.1%; P less than 0.05). The values continued to decrease, and at the end of the seventh week of the study MAP averaged 108.5 +/- 6.5 mmHg (-19.7%; P less than 0.01) in the N group, while it was 109.7 +/- 9.1 mmHg (-16.6%; P less than 0.01) in the P group. The heart rate became considerably slower in the P group only, from the initial 84.5 +/- 9.2 to 66.9 +/- 2.7 beats per minute at the end of the seventh week (-20.8%; P less than 0.01), but it was unexpectedly, although not significantly lowered also in the N group, from the initial 78.3 +/- 6.5 to 74.2 +/- 4.0 beats (-5.2%; P greater than 0.20).(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Pressure↗
PubMedDate not supplied

[Changes in left ventricular function and structure in hypertensive patients treated with methyldopa and urapidil].

In a randomized cross-over and double-blind trial twenty mild-to-moderate hypertensives (11 males, 9 females, mean age 48.4 +/- 7.6 years) were receiving methyldopa (250 mg b.i.d.) or urapidil (30 mg b.i.d.) for 7 weeks and then treated with alternative drug for additional 7 weeks, separated by one week of wash-out period. Both antihypertensives induced significant reduction (P less than 0.01) in systolic and diastolic arterial pressure, while no significant changes (P greater than 0.20) in the body weight and the heart rate were observed. The echocardiographic features of left ventricular hypertrophy (LVH) did not decrease significantly (P greater than 0.05) on either drug, except for the left ventricular posterior wall thickness (LVPWd), which decreased on methyldopa from 10.4 +/- 1.3 to 9.8 +/- 1.4 mm (P less than 0.05). The drugs under study did not change significantly the echocardiographic indices of left ventricular function. Echocardiography resulted to be more sensitive in detecting LVH than electrocardiography. It is concluded that methyldopa might successfully reduce LVH, while direct and indirect vasodilators (such as urapidil) are less effective.

Adult↗
PubMedDate not supplied

[The time interval from the onset of myocardial infarct to arrival in the coronary unit in the area of Split].

The time interval from the initial symptoms of myocardial infarction to the coronary care unit admission in patients treated at the Department of Internal Medicine, University Hospital "Firule", Split, and Military Hospital, Split, between 1 January 1981 and 31 December 1987, vas analysed. The average duration of this delay was 14.8 +/- 11.6 hours (range 2-72 hours). It is concluded that this interval should be substantially reduced in order to decrease the actual coronary heart disease death rate.

Coronary Care Units↗